Fair Value Calculator Fair Value Calculator
EN DE

0876 (0876) Fair Value & Analysis

Healthcare · Market cap HK$5.0M

0 0876 0876 · HK
PriceHK$0.0480
Fair ValueHK$0.0460
Upside-4.2%
Quality35/100
Evidence: Low Range HK$0.0443 – HK$0.0485

Fair value as of: Jul 2, 2026

From 3 valuation models · updated today

Share price −99.1% over the past month.

Price vs Fair Value (12 months)

HK$10.50 HK$0.0480 Fair Value HK$0.0460 Jun 2025 Jun 2026

12‑month range HK$0.0480 – HK$10.50 · fair‑value band HK$0.0443 – HK$0.0485 · the HK$0.0480 price screens above the HK$0.0460 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

0876 (0876) currently trades at HK$0.0480, while our model-based Fair Value estimate is HK$0.0460 — implying the stock looks roughly 4.2% overvalued today. We read business quality at 35/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

Over the trailing twelve months, 0876 generated revenue of HK$139M at a net margin of -33.6%. Revenue declined 28.2% year over year. It earns a return on equity of -11.4%. The balance sheet holds a net cash position of HK$96.1M. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$139M
Revenue growth (YoY) -28.2%
Net margin -33.6%
Return on equity -11.4%
Free cash flow −HK$58.4M FY2025
Operating margin -52.5%
More key figures
EPS growth (YoY) +433%
Net cash HK$96.1M FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

0876 reported revenue of HK$139M in FY2025 versus HK$210M in FY2021, a compound −9.7%/yr. Reported net income was −HK$46.7M in FY2025.

Revenue −9.7%/yr
FY21 HK$210M
FY22 HK$191M
FY23 HK$186M
FY24 HK$185M
FY25 HK$139M
Net income
FY21 HK$2.4M
FY22 −HK$123M
FY23 HK$7.5M
FY24 −HK$46.4M
FY25 −HK$46.7M

Is 0876 fairly valued? → Check now

Similar stocks

6 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock Price Fair Value vs Fair Value
Intuitive Surgical, Inc ISRG $402.95 $182.39 -55%
EssilorLuxottica Société anonyme ESLOF $190.25 $125.65 -34%
HOYA Corporation HOCPY $168.16 $96.16 -43%
Medline Inc MDLN $33.61 $31.78 -5%
Becton, Dickinson and Company BDX $149.56 $117.04 -22%
Alcon Inc ALC $66.11 $36.99 -44%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap Stocks

Frequently asked questions

Is 0876 (0876) undervalued?
As of Jul 2, 2026, our model estimates a fair value of HK$0.0460 versus a price of HK$0.0480 — about −4% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 0876?
Our model-based fair value for 0876 is HK$0.0460 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$0.0480.
What is the quality score of 0876?
0876 has a Quality Score of 35/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.
What is the revenue of 0876 (0876)?
0876 reported trailing-twelve-month revenue of about HK$139M (latest available figure, as of Jul 2, 2026).
What is the net profit margin of 0876?
The net profit margin of 0876 is about -33.6%, meaning it is currently running at a net loss. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.